 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || KQ-2003 / Shanghai Keqi Pharma
New P1/2 trial, CAR T-Cell Therapy: A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 25, 2024
P1/2, N=29, Recruiting, Sponsor: Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- | KQ-2003 / Shanghai Keqi Pharma
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 28, 2023
P1/2, N=24, Recruiting, Sponsor: Shanxi Province Cancer Hospital
Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jan 2022 --> Sep 2024
- | KQ-2003 / Shanghai Keqi Pharma
New P1/2 trial, CAR T-Cell Therapy: Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 18, 2021
P1/2, N=24, Recruiting, Sponsor: Shanxi Province Cancer Hospital